ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Distribution characteristics and influencing factors of active cytomegalovirus infection in patients with hematological malignancies complicated with sepsis.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCytomegalovirus (CMV) tends to reactivate in immunocompromised individuals. Patients with hematological malignancies are at high risk of CMV infection due to treatment-related immunosuppression, and sepsis may further promote latent CMV reactivation via inflammatory disorders. However, research on active CMV infection in patients with both conditions remains limited.
methodsA single-center retrospective cohort study included 119 patients with hematological malignancies complicated by sepsis (Ningbo Medical Center Lihuili Hospital, June 2022-June 2025). Patients were divided into active CMV infection group (plasma CMV DNAemia ≥ 500 copies/mL, 41 cases) and non-active group (< 500 copies/mL, 78 cases) via qPCR. Clinical features, laboratory indicators, treatment, and outcomes were compared; regression analysis screened risk factors, and ROC curves assessed predictive value of indicators.
resultsActive CMV infection incidence was 34.45%, with 92.68% occurring within 0-7 days of hospitalization. CMV was detected in lower respiratory tract specimens of 21.84% patients, and plasma CMV load correlated positively with that in these specimens (r = 0.558, P < 0.001). The active group had lower weight, BMI, hemoglobin, albumin, white blood cell and platelet counts, but higher SOFA scores and body temperature (all P < 0.05). The active group had higher rates of blood transfusion and immunosuppressant use, longer hospitalization and fever duration, and higher 28-day all-cause mortality (all P < 0.05); no difference in complication incidence was observed. Decreased white blood cell count was an independent risk factor (β=-0.209, OR = 0.811, P = 0.021) with optimal predictive value (AUC = 0.746); hemoglobin and platelet count also had good predictive value.
conclusionsPatients with hematological malignancies complicated by sepsis have high active CMV infection incidence (mostly early hospitalization), associated with poor prognosis. Decreased white blood cell count is a useful early screening indicator, requiring early clinical monitoring and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.